Biocon Limited (BIOCON) — Announcement | 25 August 2026
Biocon announced that its subsidiary Biocon Biologics received marketing approval from Japan's MHLW for a pegfilgrastim biosimilar, enabling sales in Japan through Sandoz K.K. This expands Biocon's biosimilar footprint in a high-value market and supports its global growth strategy.
About Biocon Limited (BIOCON)
Healthcare · Pharmaceuticals · Listed on NSE
📡 Get AI alerts when BIOCON files next
Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions
Track BIOCON — Free💡 Ask AI about this filing
📊 More BIOCON filings
- Announcement — 25 September 2026Biocon announced that its Malaysian subsidiary obtained MHRA approval for a new insulin fill-finish ...
- 🔴 Announcement — 21 September 2026Biocon announced that its biosimilar Pertuzumab received a positive EMA CHMP recommendation for trea...
- 🔴 Corporate Action — 9 September 2026Biocon announced a final dividend of ₹0.50 per share for FY 2025-26, approved at the August 6, 2026 ...
- 🔴 Announcement — 8 September 2026Biocon announced a 10-year supply agreement for Pertuzumab in Brazil through a partnership with Bahi...
- 🔴 Announcement — 8 September 2026Biocon announced its upcoming investor meetings schedule, including a Sep 11 roadshow in Mumbai, to ...
🔥 Also filed on 25 August 2026
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when BIOCON files new disclosures
Track BIOCON filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track BIOCON — FreeFree account · 2 AI queries/day